Omni Ab Status
The company was acquired by Ligand Pharmaceuticals (NAS:LGND) for $178 million on December 29, 2015. The deal included $92.6 million in cash and $85.4 million in Ligand common stock.
Developer of human monoclonal antibody platforms. The company develops human therapeutic antibodies based on transgenic rats for pharmaceutical companies.
Year Founded
2007
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Acquired/Merged (Operating Subsidiary)
-
Financing Status
Formerly VC-backed
Omni Ab News and Updates
With prayer and supplication, make all your needs known to God
The Tablet | May 23, 2022
Omni Logistics Unveils 100% Renewable Energy-Powered Corporate Headquarters in Dallas, TX
PR Newswire | May 23, 2022
Lyophilized Injectable Drugs Market Survey Report 2021 Along with Statistics, Forecasts till 2022- 2028 – The Daily Vale
The Daily Vale | May 20, 2022
US FOODS HOLDING CORP. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
Marketscreener.com | May 19, 2022
Research Analysts' Downgrades for May 19th (AAVMY, AMCX, BK, BRG, COLL, CRARY, CSX, DOC, ELY, FF)
Defense World | May 19, 2022
Sight Sciences, Inc. (SGHT) Q1 2022 Earnings Call Transcript
The Motley Fool | May 11, 2022
Omni Ab Primary Industry Sector / Group / Code
Omni Ab's Trends
Headquarters
-
HQ Address Line 12747 Ross Road
-
HQ Address Line 2Suite A
-
HQ CityPalo Alto
-
HQ State/ProvinceCalifornia
-
HQ Post Code94303
-
HQ CountryUnited States
Omni Ab's Keywords
mood_badFeed is empty.
Add a review